Evolus, Inc. (EOLS)
After hours:
| Previous Close | 10.93 |
| Open | 11.00 |
| Bid | 7.85 x 200 |
| Ask | 10.85 x 400 |
| Day's Range | 10.67 - 11.00 |
| 52 Week Range | 7.07 - 15.43 |
| Volume | |
| Avg. Volume | 565,915 |
| Market Cap | 679.324M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
NEWPORT BEACH, Calif., June 24, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).
- Business Wire
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
NEWPORT BEACH, Calif., June 12, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals.
- Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif., June 07, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778 shares of Evolus and an aggregate of 29,546 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of dir
